Lantern Pharma Inc
lanternpharma.comWhat Do They Do?
Develops targeted cancer drug candidates and an antibody-drug conjugate program, and plans to offer AI platforms to biopharma companies, researchers and drug developers.
10-K for FY2025, filed Mar 30, 2026We are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and…View ↗
We have active clinical programs for our three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused…View ↗
A key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our…View ↗
In addition, in 2026 we plan to introduce our proprietary artificial intelligence (AI) platforms and related technologies as a potential…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
Who Are Their Customers?
Lantern plans to serve biopharma companies, researchers, drug developers and other users through subscriptions, platform access and services.
10-K for FY2025, filed Mar 30, 2026In addition, in 2026 we plan to introduce our proprietary artificial intelligence (AI) platforms and related technologies as a potential…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$7.1MView ↗
- ▲ +63% (Loss)
- vs −$4.3M in Q2 FY2025
-
Aug 14, 2026
Lantern established Open Medicine AI as a separate company
Open Medicine AI received commercial licenses for Lantern’s models, data, algorithms and related assets and personnel.
Sources
8-K, filed Aug 14, 2026
In August 2026, Lantern announced the formal creation of Open Medicine AI (OMAI) and the execution of commercial licensing agreements…View ↗
AI platform commercialization
The earlier report described the AI platform as a tool for Lantern’s drug discovery and development; the latest report adds plans to offer selected AI modules to the broader research and drug-development community.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 30, 2026A key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our…View ↗
A key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging our…View ↗
Drug candidates advance
Candidates previously in preclinical development have advanced into clinical trials.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 30, 2026Additionally, we have two new drug candidates, LP-184 and LP-284, in pre-IND preclinical development for multiple potentially distinct…View ↗
We are conducting a targeted phase 2 trial (the Harmonic™ trial) for LP-300 in never smoking patients with advanced non-small cell lung…View ↗
Pipeline emphasis
A compound previously described as in clinical development is now framed as an additional candidate with potential for future development, after its trial was closed to focus resources on later development.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 30, 2026We currently have two drug candidates in clinical development, LP-100 and LP-300, where we are leveraging data from prior preclinical…View ↗
Who Do They Compete With?
Competes with Candel Therapeutics, Pyxis Oncology, Foghorn Therapeutics, Prelude Therapeutics, Warewolf Therapeutics, Xilio Therapeutics, Ikena Oncology, Atossa Therapeutics, Elevation Oncology, Bolt Biotherapeutics, AbCellera, Atomwise, InSilico Medicine, Iktos, Verge Genomics, Recursion Pharmaceuticals, Schrodinger, and Roivant Sciences
10-K for FY2025, filed Mar 30, 2026- Oncology-focused clinical stage companies: Candel Therapeutics, Pyxis Oncology, Foghorn Therapeutics, Prelude Therapeutics, Warewolf…View ↗
Loading...
